MX2020013817A - Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. - Google Patents
Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.Info
- Publication number
- MX2020013817A MX2020013817A MX2020013817A MX2020013817A MX2020013817A MX 2020013817 A MX2020013817 A MX 2020013817A MX 2020013817 A MX2020013817 A MX 2020013817A MX 2020013817 A MX2020013817 A MX 2020013817A MX 2020013817 A MX2020013817 A MX 2020013817A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- compounds useful
- compounds
- cell activators
- naphthyridinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula (I): (ver Fórmula) o una sal del mismo, en donde: R1, R2, R3, R4, R5, y m son definidos en el presente documento. También se describen métodos para usar tales compuestos para inhibir la actividad de uno o ambos de diacilglicerol cinasa alfa (DGKa) y diacilglicerol cinasa zeta (DGK?), y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son útiles en el tratamiento de infecciones virales y trastornos proliferativos, como el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690439P | 2018-06-27 | 2018-06-27 | |
| US201962840459P | 2019-04-30 | 2019-04-30 | |
| PCT/US2019/039135 WO2020006018A1 (en) | 2018-06-27 | 2019-06-26 | Substituted naphthyridinone compounds useful as t cell activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020013817A true MX2020013817A (es) | 2021-03-09 |
Family
ID=67439335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020013817A MX2020013817A (es) | 2018-06-27 | 2019-06-26 | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10669272B2 (es) |
| EP (1) | EP3814348B9 (es) |
| JP (1) | JP7432532B2 (es) |
| KR (1) | KR102767739B1 (es) |
| CN (1) | CN112654621B (es) |
| AU (1) | AU2019291794B2 (es) |
| BR (1) | BR112020026681A2 (es) |
| CA (1) | CA3104654A1 (es) |
| CL (1) | CL2020003260A1 (es) |
| DK (1) | DK3814348T3 (es) |
| ES (1) | ES2960754T3 (es) |
| FI (1) | FI3814348T3 (es) |
| HR (1) | HRP20231253T1 (es) |
| HU (1) | HUE064531T2 (es) |
| IL (1) | IL279728B2 (es) |
| LT (1) | LT3814348T (es) |
| MX (1) | MX2020013817A (es) |
| PE (1) | PE20210469A1 (es) |
| PL (1) | PL3814348T3 (es) |
| PT (1) | PT3814348T (es) |
| RS (1) | RS64641B1 (es) |
| SG (1) | SG11202012972YA (es) |
| SI (1) | SI3814348T1 (es) |
| SM (1) | SMT202300466T1 (es) |
| TW (1) | TW202019924A (es) |
| WO (1) | WO2020006018A1 (es) |
| ZA (1) | ZA202100555B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
| MX2021013135A (es) | 2019-04-29 | 2021-11-25 | Solent Therapeutics Llc | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2. |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| BR112022010112A2 (pt) | 2019-11-28 | 2022-09-06 | Bayer Ag | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica |
| EP4065584A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| EP4065570A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| JP2023510108A (ja) * | 2019-12-19 | 2023-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ |
| IL294273A (en) * | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted heteroaryl compounds useful as t cell activators |
| AR120823A1 (es) * | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| US20230118629A1 (en) * | 2019-12-23 | 2023-04-20 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as t cell activators |
| IL294269A (en) * | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| AR120896A1 (es) * | 2019-12-25 | 2022-03-30 | Astellas Pharma Inc | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz |
| LT4139286T (lt) * | 2020-04-24 | 2025-05-12 | Bayer Aktiengesellschaft | Pakeisti aminotiazolai kaip dgkzeta inhibitoriai imuniteto aktyvavimui |
| WO2021258010A1 (en) * | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| JP7604067B2 (ja) * | 2020-11-26 | 2024-12-23 | エルジー・ケム・リミテッド | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 |
| AU2021389180A1 (en) * | 2020-11-30 | 2023-06-29 | Astellas Pharma Inc. | Heteroaryl carboxamide compound |
| WO2022133083A1 (en) | 2020-12-16 | 2022-06-23 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| EP4301755A1 (en) | 2021-03-03 | 2024-01-10 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| US11932634B2 (en) * | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| EP4472963A1 (en) * | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| CN118829642A (zh) * | 2022-03-01 | 2024-10-22 | 英矽智能科技知识产权有限公司 | 二酰基甘油激酶(DGK)α抑制剂及其用途 |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| AU2023227010A1 (en) | 2022-03-01 | 2024-09-12 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| AR131785A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinaciones de inhibidores de dgk (diacilglicerol quinasa) |
| CN116375654B (zh) * | 2023-03-22 | 2024-12-31 | 湖北三峡实验室 | 一种由双甘肽制备2,5-二酮哌嗪的方法 |
| CN119143715B (zh) * | 2024-11-12 | 2025-03-14 | 天津匠新致成科技有限公司 | 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| BR0312204A (pt) | 2002-06-27 | 2005-04-26 | Schering Ag | Antagonista de receptor ccr5 de quinolina substituìda |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| JP2006521400A (ja) | 2003-03-26 | 2006-09-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び関連障害の処置のための化合物及びそれらの使用 |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| CN1867334A (zh) | 2003-07-22 | 2006-11-22 | 詹森药业有限公司 | 作为c－fms激酶抑制剂的喹啉酮衍生物 |
| CN1839133A (zh) * | 2003-08-22 | 2006-09-27 | 阿文尼尔药品公司 | 作为巨噬细胞移动抑制因子的抑制剂的取代的二氮杂萘衍生物及其在治疗人类疾病中的应用 |
| US7381401B2 (en) * | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| EA026785B1 (ru) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Модуляторы индоламин 2,3-диоксигеназы и способы их применения |
| ME02260B (me) | 2005-07-01 | 2016-02-29 | Medarex Inc | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| JP5294874B2 (ja) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環 |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| US20080125470A1 (en) | 2006-09-19 | 2008-05-29 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| EP2227233B1 (en) | 2007-11-30 | 2013-02-13 | Newlink Genetics | Ido inhibitors |
| KR20110013421A (ko) | 2008-05-29 | 2011-02-09 | 생-고뱅 생트레 드 레체르체 에 데투드 유로삐엔 | 알루미늄 티타네이트 함유 다공질 구조물 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| MY188826A (en) | 2008-12-09 | 2022-01-06 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2010088408A2 (en) | 2009-01-28 | 2010-08-05 | Emory University | Subunit selective nmda receptor antagonists for the treatment of neurological conditions |
| EP3023438B1 (en) | 2009-09-03 | 2020-03-11 | Merck Sharp & Dohme Corp. | Anti-gitr antibodies |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2557454T3 (es) | 2009-12-10 | 2016-01-26 | F. Hoffmann-La Roche Ag | Anticuerpos que se unen al dominio extracelular 4 de CSF1R humana y su utilización |
| MA34062B1 (fr) | 2010-03-04 | 2013-03-05 | Macrogenics Inc | Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| EP2542587A1 (en) | 2010-03-05 | 2013-01-09 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| TW202112827A (zh) | 2010-05-04 | 2021-04-01 | 美商戊瑞治療有限公司 | 與集落刺激因子１受體（ｃｓｆ１ｒ）結合之抗體類 |
| EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
| KR101527297B1 (ko) | 2010-09-09 | 2015-06-26 | 화이자 인코포레이티드 | 4-1ｂｂ 결합 분자 |
| WO2012142498A2 (en) | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| SMT201800294T1 (it) | 2011-04-20 | 2018-07-17 | Medimmune Llc | Anticorpi e altre molecole che legano b7-h1 e pd-1 |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| EP2791174B1 (en) | 2011-12-15 | 2018-02-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r and uses thereof |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR089939A1 (es) | 2012-02-09 | 2014-10-01 | Glenmark Pharmaceuticals Sa | COMPUESTOS BICICLICOS COMO INHIBIDORES DE mPGES-1 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CA2882804A1 (en) | 2012-08-31 | 2014-03-06 | Brian Wong | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| US9937205B2 (en) | 2012-09-04 | 2018-04-10 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive T cell transfer |
| CA2981530A1 (en) | 2015-04-10 | 2016-10-13 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2981114T3 (es) | 2015-12-17 | 2024-10-07 | Merck Patent Gmbh | 8-ciano-5-piperidino-quinolinas como antagonistas de TLR7/8 y sus usos para el tratamiento de trastornos inmunitarios |
| CN107216325B (zh) | 2016-03-22 | 2019-06-25 | 上海医药工业研究院 | 萘啶酮类化合物、及其制备方法和应用 |
| WO2017177037A1 (en) | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| EP4001269A1 (en) | 2016-12-22 | 2022-05-25 | Amgen Inc. | Benzoisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| WO2018134885A1 (ja) | 2017-01-17 | 2018-07-26 | 初実 田中 | 支援奨励システムおよび支援奨励方法 |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
| SI3761980T1 (sl) | 2018-03-07 | 2024-06-28 | Pliant Therapeutics, Inc. | Aminokislinske spojine in postopki uporabe |
| US20210238136A1 (en) | 2018-06-07 | 2021-08-05 | Daiichi Sankyo Company, Limited | Azetidine derivative, and prodrug thereof |
| KR20210024532A (ko) | 2018-06-27 | 2021-03-05 | 바이오젠 엠에이 인코포레이티드 | Ask1 억제제 |
| CN112585132B (zh) | 2018-06-27 | 2025-02-28 | 优曼尼蒂公司 | 蛋白酶体活性增强化合物 |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
| IL279786B2 (en) | 2018-06-27 | 2025-02-01 | Reborna Biosciences Inc | Preventive or therapeutic agent for spinal muscular atrophy |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| EP3814350A4 (en) | 2018-06-27 | 2022-05-04 | Oscotec Inc. | PYRIDOPYRIMIDINONE DERIVATIVES FOR USE AS AXL INHIBITORS |
-
2019
- 2019-06-26 SG SG11202012972YA patent/SG11202012972YA/en unknown
- 2019-06-26 JP JP2020572691A patent/JP7432532B2/ja active Active
- 2019-06-26 HR HRP20231253TT patent/HRP20231253T1/hr unknown
- 2019-06-26 US US16/452,679 patent/US10669272B2/en active Active
- 2019-06-26 LT LTEPPCT/US2019/039135T patent/LT3814348T/lt unknown
- 2019-06-26 RS RS20230895A patent/RS64641B1/sr unknown
- 2019-06-26 FI FIEP19744923.4T patent/FI3814348T3/fi active
- 2019-06-26 PL PL19744923.4T patent/PL3814348T3/pl unknown
- 2019-06-26 EP EP19744923.4A patent/EP3814348B9/en active Active
- 2019-06-26 PE PE2020002111A patent/PE20210469A1/es unknown
- 2019-06-26 AU AU2019291794A patent/AU2019291794B2/en active Active
- 2019-06-26 HU HUE19744923A patent/HUE064531T2/hu unknown
- 2019-06-26 SI SI201930609T patent/SI3814348T1/sl unknown
- 2019-06-26 BR BR112020026681-7A patent/BR112020026681A2/pt unknown
- 2019-06-26 CN CN201980055715.8A patent/CN112654621B/zh active Active
- 2019-06-26 DK DK19744923.4T patent/DK3814348T3/da active
- 2019-06-26 CA CA3104654A patent/CA3104654A1/en active Pending
- 2019-06-26 MX MX2020013817A patent/MX2020013817A/es unknown
- 2019-06-26 SM SM20230466T patent/SMT202300466T1/it unknown
- 2019-06-26 ES ES19744923T patent/ES2960754T3/es active Active
- 2019-06-26 WO PCT/US2019/039135 patent/WO2020006018A1/en active IP Right Grant
- 2019-06-26 KR KR1020217002231A patent/KR102767739B1/ko active Active
- 2019-06-26 PT PT197449234T patent/PT3814348T/pt unknown
- 2019-06-27 TW TW108122537A patent/TW202019924A/zh unknown
-
2020
- 2020-04-08 US US16/843,024 patent/US10954238B1/en active Active
- 2020-12-16 CL CL2020003260A patent/CL2020003260A1/es unknown
- 2020-12-23 IL IL279728A patent/IL279728B2/en unknown
-
2021
- 2021-01-26 ZA ZA2021/00555A patent/ZA202100555B/en unknown
- 2021-02-01 US US17/164,009 patent/US11713316B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| MX2020013373A (es) | Compuestos de naftiridinona utiles como activadores de celulas t. | |
| MX2022007130A (es) | Derivados de piperazina sustituidos utiles como activadores de celulas t. | |
| ZA202203515B (en) | Substituted pyridopyrimidinonyl compounds useful as t cell activators | |
| MX2022007842A (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t. | |
| MX2022007372A (es) | Compuestos de heteroarilo sustituidos utiles como activadores de celulas t. | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| PH12020500529A1 (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| PH12017500367A1 (en) | Compounds that inhibit mcl-1 protein | |
| TN2018000119A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MX2023014492A (es) | Compuestos utiles en la terapia para el vih. | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| MY192861A (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| MX2023011408A (es) | Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer. | |
| MY194711A (en) | Novel annelated phenoxyacetamides | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| TN2016000459A1 (en) | Cycloalkyl-linked diheterocycle derivatives. | |
| TW201713630A (en) | Substituted quinazoline compounds and methods of use thereof |